Inspira Technologies VORTX™ Tech Hits 99%+ Gas Exchange Efficiency

Ticker: IINNW · Form: 6-K · Filed: Apr 23, 2025 · CIK: 1837493

Sentiment: bullish

Topics: medical-device, technology-milestone, animal-testing

TL;DR

Inspira's VORTX™ tech shows >99% gas exchange efficiency in animal tests. Big step forward.

AI Summary

On April 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced successful in-vivo animal testing for its VORTX™ technology, achieving over 99% gas exchange efficiency. This milestone is detailed in a press release furnished as Exhibit 99.1 with their Form 6-K filing.

Why It Matters

This high efficiency in animal testing is a critical step towards potential human clinical trials, signaling significant progress for Inspira's respiratory support technology.

Risk Assessment

Risk Level: medium — While positive, the results are from animal testing and require further clinical trials and regulatory approval for human application.

Key Numbers

Key Players & Entities

FAQ

What specific animal model was used for the VORTX™ technology testing?

The filing does not specify the animal model used for the VORTX™ technology testing.

When does Inspira Technologies plan to initiate human clinical trials?

The filing does not provide a timeline for the initiation of human clinical trials.

What is the primary indication for the VORTX™ technology?

The filing implies the VORTX™ technology is for respiratory support, given its gas exchange efficiency.

Is the press release detailing these results included as an exhibit?

Yes, the press release titled 'Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing' is furnished as Exhibit 99.1.

What is the filing number for this report?

The filing number (Accession Number) for this report is 0001213900-25-034345.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2025 regarding Inspira Technologies OXY B.H.N. Ltd (IINNW).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing